Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

52.43 +0.55 (+1.06%)
Delayed Quote Updated: 11:47 AM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
38 39 Next >
News headline image
Genentech and Breastcancer.org Say It’s “About Damn Time” We Talk About What Happens When Initial Breast Cancer Treatment Ends
From Genentech
Via Business Wire
News headline image
Genentech Presents New Data at EURETINA, Highlighting Vabysmo’s Real-World Effectiveness and Safety Across Major Retinal Conditions
From Genentech
Via Business Wire
News headline image
Genentech’s Giredestrant Combination Significantly Improved Progression-Free Survival in ER-positive Advanced Breast Cancer in Phase III evERA Data Published in The New England Journal of Medicine
From Genentech
Via Business Wire
News headline image
Could This Company Challenge Eli Lilly and Novo Nordisk in the Weight Loss Market? ↗
Roche is increasingly looking like a notable contender in this fast-growing area. 
Via The Motley Fool
News headline image
Genentech’s Fenebrutinib Is the First BTK Inhibitor to Receive U.S. FDA Filing Acceptance in Both Relapsing and Primary Progressive Multiple Sclerosis
From Genentech
Via Business Wire
News headline image
Genentech Breaks Ground on $750 Million Manufacturing Expansion in Hillsboro, Oregon
From Genentech
Via Business Wire
News headline image
Positive Interim Data Shows Genentech’s Sefaxersen Significantly Reduces Proteinuria in People With IgA Nephropathy (IgAN)
From Genentech
Via Business Wire
News headline image
Is Regeneron Stock a Bargain Below $800? ↗
The past couple of years have been challenging for the company, but there is a light at the end of the tunnel. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Genentech Announces Positive Phase II Results for Dual GLP-1/GIP Receptor Agonist Enicepatide in People Living With Type 2 Diabetes and Overweight or Obesity
From Genentech
Via Business Wire
News headline image
BioNTech Threw in the Towel on Its Colorectal Cancer Vaccine Trial. Should Investors Be Worried? ↗
BioNTech's recent pipeline setback is a real cause of concern. But investors shouldn't panic. 
Via The Motley Fool
News headline image
Genentech and Roche Announce Grand Opening of Boston R&D Innovation Center
From Genentech
Via Business Wire
News headline image
Genentech’s Lunsumio-Based Regimen Significantly Improves Progression-Free Survival in Follicular Lymphoma in Phase III CELESTIMO Study
From Genentech
Via Business Wire
News headline image
U.S. FDA Grants Priority Review for Genentech’s Enspryng for MOGAD, an Autoimmune Disease With No Approved Treatments
From Genentech
Via Business Wire
A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach
Via Investor Brand Network
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial
Via Investor Brand Network
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial
Via Investor Brand Network
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial
Via Investor Brand Network
News headline image
A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach
From BioMedWire
Via GlobeNewswire
News headline image
Revolution Medicines Got Its Breakthrough—What Moves It Next? ↗
FDA approved Revolution Medicines' RASONQUE for pancreatic cancer, but RVMD stock stayed flat as investors had priced in the news early, with rising expenses now in focus. 
Via MarketBeat
News headline image
Here's Why Ionis Pharmaceuticals' Steep Sell-off Was Overdone ↗
This biotech stock looks like a great candidate to buy on the admittedly steep dip. 
Via The Motley Fool
News headline image
2 Stocks That Could Capitalize on the GLP-1 Boom ↗
They aren't the most prominent names in the GLP-1 space, but they are worth a second look. 
Via The Motley Fool
News headline image
Genentech Announces Manufacturing Expansion in Hillsboro, Oregon
From Genentech
Via Business Wire
News headline image
Genentech Marks Topping out Milestone for New Holly Springs, North Carolina Manufacturing Facility
From Genentech
Via Business Wire
News headline image
2 GLP-1 Stocks That Could Double Your Money by 2031 ↗
They are fairly risky, but their potential upside is massive. 
Via The Motley Fool
News headline image
Vanguard Is Bullish on Developed Markets Outside the U.S. -- But How Can You Buy Them? These 2 ETFs Can Help. ↗
Want to put your money into global stocks that might be big winners from AI? These two low-cost ETFs offer international diversification. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Economy
News headline image
FDA Grants Priority Review to Genentech’s Gazyva for Adults With Primary Membranous Nephropathy
From Genentech
Via Business Wire
News headline image
Should You Buy Eli Lilly Stock? Here's My Honest Take. ↗
There are good reasons to invest in Lilly and to hold off. 
Via The Motley Fool
News headline image
VYMI vs. VIGI: Which International Dividend ETF Is Better? ↗
When buying international dividend stocks, diversification is likely the best bet. 
Via The Motley Fool
Topics Artificial Intelligence ETFs
News headline image
The Market Just Got Shaken—These 3 ETFs May Come Out Stronger ↗
As Middle East tensions resurface and futures drop, VIG, VIGI, and FDVV offer dividend growth ETFs combining income with exposure to technology and global equities. 
Via MarketBeat
Topics Artificial Intelligence ETFs Stocks
News headline image
Genentech and Roche Present New Data in Alzheimer’s Disease From Across Its Integrated Pharmaceutical and Diagnostics Portfolio at AAIC
From Genentech
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
38 39 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.